Novavax to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Operational Highlights on August 8, 2024

GAITHERSBURG, Md., Aug. 1, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M(TM) adjuvant, today announced it will report its second quarter 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, August 8, 2024. Details of the event and replay are as follows:

     Conference call details:





     Date:                    
     August 8, 2024





     Time:                    
     8:30 a.m. U.S. ET





     URL to register phone:                https://emportal.ink/
                                             3XTduSS





     Dial-in number:            (800) 836-8184 (Domestic) or


                                              (+1) (646) 357-8785
                                                  (International)





     Webcast:                              ir.novavax.com/events

    --  Participants can join the conference call without operator assistance by
        registering and entering their phone number with the above URL to
        receive an instant automated call back.
    --  Participants can also dial direct to be entered into the call by an
        operator and will be prompted to request to join the Novavax, Inc. call.
    --  To ensure a timely connection, it is recommended that participants join
        at least 10 minutes prior to the scheduled webcast.

     Replay
      details:




     Date:       Available starting at 11:30 a.m. ET, August 8, 2024, until 11:59 p.m. U.S.
                  ET, August 15, 2024




     Dial-in
      number:  
     (888) 660-6345 (Domestic) or


                                             
              (+1) (646) 517-4150 (International)




     Passcode: 
     52500#




     Webcast:  
     
                ir.novavax.com/events, until September 8, 2024

About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information.

Contacts:

Investors
Erika Schultz
240-268-2022
ir@novavax.com

Media
Giovanna Chandler
202-709-5563
media@novavax.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-host-conference-call-to-discuss-second-quarter-2024-financial-results-and-operational-highlights-on-august-8-2024-302212235.html

SOURCE Novavax, Inc.